Show simple item record

dc.contributor.authorAri S. Nugraha
dc.date.accessioned2018-03-22T02:45:24Z
dc.date.available2018-03-22T02:45:24Z
dc.date.issued2018-03-22
dc.identifier.issn1693-3591
dc.identifier.urihttp://repository.unej.ac.id/handle/123456789/84811
dc.descriptionPHARMACY, Vol 02 No 05 Agustus 2007en_US
dc.description.abstractGlobalization has contributed to the development of pharmaceutical industries in terms of medical exploration and trade among countries around the world. A number of pharmaceutical companies have been established throughout the world and become international businesses. Nowadays, pharmaceutical businesses in developed countries are more likely to embrace global agreement on intellectual properties and trade designed to keep competition fair. Multinational Pharmaceutical Companies (most of them are from developed countries) play a large role in both drug development and supply. According to ABPI in 2004, more than 60% of the world’s drugs consumption is supplied by only 20 big pharmaceutical corporations. Can it be argued that multinational pharmaceutical companies give benefit for pharmaceutical companies and people in developing countries around the world? This article will focus on several negative impacts occurred on developing countries.en_US
dc.description.sponsorshipPHARMACY: Jurnal Farmasi Indonesia Pharmaceutical Journal of Indonesiaen_US
dc.language.isoenen_US
dc.subjectglobalizationen_US
dc.subjectpharmaceutical industriesen_US
dc.subjectdeveloping countriesen_US
dc.titleGLOBAL PHARMACEUTICAL INDUSTRIES, DRUGS EXPLORATION AND PATENTING: IMPACT ON DEVELOPING COUNTRIESen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record